Markus Muttenthaler

Breast cancer impacts one in eight women globally, resulting in over half a million deaths each year. Current diagnostic methods fall short, with approximately 40 percent of breast cancers having already spread at the time of diagnosis and mammography often producing high rates of false positives. In the project “Peptide Tracers”, Markus Muttenthaler addresses these challenges by developing theranostic peptide tracers pursuing new targets for imaging, diagnosis and treatment of breast cancer. These tracers can enhance patient care, treatment options, and survival rates while reducing healthcare costs.